American Oriental Bioengineering to Launch New Boke Brand Osteoporosis Drug

NEW YORK, Aug. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced the commercial launch of Boke brand Yi Shen Jian Gu Gel ("YSJG" Gel) after successful test marketing in the second quarter of 2010.

Boke YSJG Gel aims at alleviating osteoporosis. A report issued by China's Ministry of Health ("MOH") shows that between 35 and 40 million people in China, or about 3% of the population, have osteoporosis, and the number of patients is expected to increase to 150 million by the year 2025.

The main active ingredient of YSJG Gel is Rhizoma Homalomenae, as well as ginseng, safflower, and fleece flower root, and is granted proprietary status by China's SFDA.

Mr. Tony Liu, Chairman and CEO of AOBO, commented, "The addressable market is large and growing for this product. We intend to make use of YSJG's proprietary drug status and Boke's brand image in our marketing."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Forward-Looking Statements

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2010, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

    For more information, please contact:

     ICR, LLC
     Christine Duan or Ashley Ammon
     Phone: [phone]

SOURCE American Oriental Bioengineering, Inc.

Copyright g. 9 PR Newswire